Xintela strengthens its organisation

Xintela strengthens its organisation wih the appointment of Caroline Ehrencrona as Director Clincial Development and Regulatory Affairs

Read as PDF

Xintela announces the appointment of Caroline Ehrencrona to a role responsible for the company’s Clinical Development and Regulatory Affairs operations. Caroline Ehrencrona takes up the post on June 1 2016 and will strengthen Xintela’s operations for upcoming clinical studies and will be responsible for the day-to-day contact with regulatory authorities.

Caroline Ehrencrona has more than ten years experience in the biotech industry and has most recently held a post as Project Director & QA Manager at TikoMed AB, Sweden. Caroline Ehrencrona has broad experience in both pre-clinical and early clinical research, with special emphasis on toxicology but also contact with regulatory authorities and quality assurance.  

– For Xintela, it’s really important to strengthen the team with experience of clinical development and regulatory issues so that we can effectively drive our projects forward into clinical phases.  Caroline’s broad experience of drug development and contact with regulatory authorities – in combination with her background as a researcher – are very valuable additions to the company, says Xintela’s CEO Evy Lundgren-Åkerlund.

In addition to her broad experience from the biotech industry, Caroline Ehrencrona has a PhD in biomedical science and an MSc in chemistry from University of Kalmar. She has also research experience from the University of Lund.

 – Xintela’s strong portfolio and unique projects bode well for the future. Within the company, there is both the knowledge and competence needed to assert themselves in the field. I am looking forward to developing the clinical programme and to maintaining contact with the authorities to ensure that our studies and applications are approved. It will be very interesting to develop projects within the fields of regenerative medicine and cancer with the Xintela team, says Caroline Ehrencrona.

 In addition to good planning, future clinical studies demand excellent contacts with regulatory authorities such as The Swedish MPA (Läkemedelsverket) and the European Medicines Agency (EMA). Caroline Ehrencrona,will work with the design and conduct of safety studies and future clinical programmes with CEO Evy Lundgren-Åkerlund and Research Director Carl-Magnus Högerkorp.


Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel:+46 70-329 18 71
Medicon Village 223 81 Lund, Sweden

Queries regarding trading with Xintela shares and warrants will be answered by the company’s Certified Adviser, Consensus Asset Management AB. Telephone: +46 31-745 50 00.


Media and Investor Relations related queries should be directed to:
Adam Lindblom, Laika Consulting
Tel: +46 73-062 20 13

About Xintela 
Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours.  The Company was founded in 2009, but research and development started in 2013. The key to Xintela's business is the Company's patented marker technology, XINMARK™. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces.  The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK™-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Consensus Asset Management AB.     


Information submitted for publication 1 June 2016 08.30 CET


Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

December 29, 2017
Xintela licenses human antibody technology for cancer therapy
December 19, 2017
Xintela to collaborate with Japanese CellSeed Inc.
November 13, 2017
Xintela raises 17 million SEK in debt and equity
October 17, 2017
Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons.
September 11, 2017
Xintela building own GMP-facility for stem cell production
July 17, 2017
Xintela recruits Liselotte Theorell as Director Product Development and Quality Management
June 22, 2017
Xintela participates in multi-million, government funded initiative to form a cell and gene therapy research center
May 22, 2017
Xintela signs Memorandum of Understanding with the leading European cell therapy company, CO.DON
May 9, 2017
Xintela: Keld Sondergaard nominated as new board member
March 21, 2017
Xintela announces today that Thomas Areschoug has been recruited to the business development team......
February 8, 2017
(In Swedish) Xintela: Insynspersoner och huvudägare avser nyttja teckningsoptioner av serie TO1
January 20, 2017
Xintela reports positive preclinical results in cancer project
January 4, 2017
Xintela´s stem cells show positive treatment effects on cartilage damage in horse study
December 22, 2016
Xintela reports positive results from completed horse study
September 12, 2016
Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016.
August 22, 2016
Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation.
June 23, 2016
Xintela announces that Christer Betsholtz has been engaged as a scientific and strategic advisor
June 1, 2016
Xintela strengthens its organisation wih the appointment of Caroline Ehrencrona as Director Clincial Development and Regulatory Affairs
April 25, 2016
Xintela initiates a study on the treatment of cartilage damage in horses in the USA.
March 16, 2016
Xintela's press releases are currently only published in Swedish. Please contact us if you have further questions.
January 5, 2018
Pre-Christmas breakthrough promises an exciting 2018
September 28, 2017
‍Strategic decisions that builds significant value
July 19, 2017
Focusing on Stem Cell Production and Preparations for Clinical Trials
May 16, 2017
On the 21st March 2017, Xintela reported that it was strengthening its Business Development team...
April 5, 2017
A word from the CEO
April 5, 2017
The subscription period for shares supported by warrants has started
December 29, 2016
A Year of Significant Progress
December 14, 2016
Glioblastoma—Xintela's Focus in the Cancer Arena
November 8, 2016
Starting the Autumn with an increased focus on Xintela’s commercial development
October 19, 2016
Since our listing in the Spring, the company has developed in a very positive way and we are on track with the milestones we have set.
August 11, 2016
Confidence in the future with a strong organisation
August 11, 2016
Welcome to Xintela's newsletter
February 22, 2018
Year-End Report 2017
February 9, 2017

Dr. Marcus Keep comments on Xintelas glioblastoma project.

January 31, 2017

Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.

January 30, 2017

Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.

December 28, 2016

In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.

December 13, 2016

See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.

March 24, 2016

See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).

March 22, 2016

See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.

March 16, 2016

Investor presentation from Lund - Jan 27

March 15, 2016

Interview with Xintelas CEO

March 23, 2016
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
March 23, 2016
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
March 23, 2016
(Article in Swedish) Xintela covered in Life Science Sweden
February 24, 2016
(Article in Swedish) Rapidus: Xintela på väg till First North
March 17, 2016
Future financial analyses of Xintela will be published here.